Abstract: The invention relates to lentiviral vector particles pseudotyped with a determined heterologous viral envelope protein or viral envelope proteins originating from a RNA virus and which comprise in its genome at least one recombinant polynucleotide encoding at least one polypeptide(s) carrying epitope(s) of an antigen of a Plasmodium parasite capable of infecting a mammalian host. The lentiviral vector particles are used in order to elicit an immunological response against malaria parasites.

Abstract: The present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis C virus (HCV).

Abstract: A method for producing a polypeptide, includes at least one native ligation step using a peptide functionalized with a selenium group. The selenium peptides and compounds are also described.

Abstract: The present invention discloses an in vitro method for diagnosing a Leptospira infection in a biological sample of a subject, comprising a step of contacting said sample with bacterial cells of a serovar of the Leptospira fainei species, preferably bacterial cells of the Leptospira fainei serovar Hurstbridge, or an antigenic fraction of said bacterial cells. In a preferred embodiment, said Leptospira infection is not due to bacteria belonging to the serovar of the Leptospira fainei species used in the diagnostic method.

Abstract: The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n (I) wherein M, T, B and n ore as defined in claim 1.

Abstract: The present invention relates to the field of fibrosis and inflammation and more particularly to the use of ADAM12 (A Disintegrin and Metalloproteinase 12) inhibitors to prevent or treat inflammation-induced fibrosis. The present invention also relates to the use of ADAM12 as a marker for inflammation-induced fibrosis and to the ablation of ADAM12 expressing cells as therapeutic approach to interfere with the development of pro-fibrotic cells.

Abstract: The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres), said support being previously coated with an AGT substrate. This coupling is mediated by the irreversible reaction of the AGT enzyme on its substrate. The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.

Abstract: The invention provides methods for the identification of patients capable of controlling HIV progression, as well as to the identification of an antagonist form of IP-10 associated to HIV progression control and the uses thereof for improving the immunological response of HIV patients.

Abstract: The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.

Abstract: The invention encompasses a lentiviral packaging vector comprising a non-subtype B gag-pol sequence, particularly a subtype D gag-pol sequence. The invention further encompasses methods for making and using these vectors. The invention further encompasses lentiviral vector particles comprising HIV-1 non-subtype B Gag and/or Pol proteins.

Abstract: The present invention relates to variable domain of a camelid heavy-chain antibodies directed to amyloid ? and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid ? deposits.

Abstract: The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject.

Abstract: The present invention discloses an in vitro method for diagnosing a Leptospira infection in a biological sample of a subject, comprising a step of contacting said sample with bacterial cells of a serovar of the Leptospira fainei species, preferably bacterial cells of the Leptospira fainei serovar Hurstbridge, or an antigenic fraction of said bacterial cells. In a preferred embodiment, said Leptospira infection is not due to bacteria belonging to the serovar of the Leptospira fainei species used in the diagnostic method.

Abstract: The invention relates to mutant CyaA/E570Q+K860 polypeptides suitable for use as proteinaceous vectors for delivering one or more molecules of interest into a cell, in particular into a cell expressing the CD11b receptor. The invention further relates to polypeptide derivatives suitable for eliciting an immune response in a host. The invention is more particularly directed to polypeptides derived from an adenylate cyclase protein (CyaA) either under the form of a toxin or of a toxoid, which are mutant polypeptides. The mutant polypeptides are capable of retaining the binding activity of native CyaA to a target cell and preferably of also retaining the translocating activity of native CyaA through its N-terminal domain into target cells and furthermore have a pore-forming activity which is reduced or suppressed as compared to that of the native CyaA toxin.

Abstract: The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain. It also concerns the preparation of immunogenic compositions using said cDNA.

Abstract: A method for the treatment and/or the prevention of a disease or a symptom related to dysfunction of regulatory T cell immunomodulation includes administering to a subject in need thereof compositions that regulate regulatory T cell immunomodulatory function, in which the compositions may be prepared by contacting starting materials with phosphorylation pathway-related factors, the agonists or the antagonists thereof. The phosphorylation pathway-related factors are selected from: proto-oncogene protein PIM1 and the coding sequence thereof. The regulation is achieved by regulating the activity of regulators of regulatory T cells selected from the group: FOXP3, IL-2, GITR, CTLA4, and a combination thereof.

Abstract: The present invention relates to a methodology for the generation of infectious ribonucleoparticles (RNPs) of negative-strand RNA viruses, and in particular of non-segmented negative-strand RNA viruses in yeast, especially in budding yeast. Accordingly, the patent application relates to a recombinant yeast strain suitable for the rescue of infectious non-segmented negative-strand RNA virus particles or infectious virus-like particles. The invention also relates to the use of the recombinant yeast to prepare vaccine seed and to the use of the produced RNPs or RNPs-like to prepare vaccine formulations. It also concerns the use of the recombinant yeast for the screening of libraries of DNA.

Abstract: A method of assembling a sequence representing pieces of at least one chromosome from a set of raw sub-sequences representing DNA fragments of a library including DNA fragments including chains of contiguous nucleotides and including DNA fragments including combinations of at least two chains of contiguous nucleotides. After having obtained first values representing contact frequencies between DNA regions, the first values being associated with second values representing distances between the corresponding DNA regions, the method includes: updating a genome structure based on the first and second values and based on a theoretical model associating a contact probability between DNA regions with a distance between the corresponding DNA regions, the updated genome structure being representative of the real genome structure of the chromosome; and updating parameters of the theoretical model as a function of the updated genome structure.

Abstract: The present invention relates to the use of variable domains of camelid heavy-chain antibodies (VHH domains) directed against an intracellular target and having an isoelectric point of at least 8.5, for targeting said intracellular target or for the preparation of a peptide vector. Particularly, it concerns VHH domains directed against a glial fibrillary acidic protein and uses thereof for preparing therapeutic or diagnostic agents.

Abstract: The invention relates to a double-stranded polynucleotide comprising on its positive strand considered from its 5? end to its 3? end, (i) a promoter of a gene of interest or several promoters of various genes of interest selected among genes which are endogenous to a determined cell, and, (ii) one or several barcode(s) wherein each barcode contains at least one barcode unit formed of at least one, especially of multiple, recognition binding sites each binding site being composed of a nucleotide sequence, and wherein each of said barcode(s) is under the control of at least one of said promoter(s) for transcription. It further concerns use of said polynucleotide to monitor gene expression patterns in living cells, especially in single cells, with a rapid and high spatio-temporal resolution.